Genmab A (GMAB) Other financing activities (2023 - 2026)
Genmab A's (GMAB) quarterly Other financing activities came in at $2.0 million in Q1 2026, up 100.0% YoY from $1.0 million in Q1 2025, and down 87.5% on a QoQ basis from $16.0 million in Q3 2025.
Genmab A (GMAB) Other financing activities (2023 - 2026) Analysis & Trends
Genmab A (GMAB) has 4 years of Other financing activities data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Other financing activities rose 100.0% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.0 million (down 46.94% YoY) and the FY2024 annual result came in at $19.0 million, down 9.52% from the prior year.
- Other financing activities slipped to $2.0 million in Q1 2026, from $16.0 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $21.0 million in Q4 2023 to a low of $1.0 million in Q1 2025.
- A 4-year average of $11.6 million and a median of $11.0 million in 2024 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2025 — Other financing activities tumbled 88.89% — and 2026, when it surged 100.0%.
- Tracing GMAB's Other financing activities over 4 years: stood at $21.0 million in 2023, then fell by 9.52% to $19.0 million in 2024, then slipped by 15.79% to $16.0 million in 2025, then tumbled by 87.5% to $2.0 million in 2026.
- The last three Other financing activities figures came in at $2.0 million (Q1 2026), $16.0 million (Q3 2025), and $7.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Sep 30, 2025 | 16.00 Mn |
| Sep 30, 2025 | 16.00 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 19.00 Mn |
| Dec 31, 2024 | 19.00 Mn |
| Sep 30, 2024 | 18.00 Mn |
| Sep 30, 2024 | 18.00 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | 21.00 Mn |
| Dec 31, 2023 | 21.00 Mn |